New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
08:00 EDTAEGRAegerion subpoena not a 'major surprise,' says Leerink
Leerink views the Aegerion's subpoena from the U.S. Department of Justice as not a "major surprise" after the FDA reprimanded the company for statements made by its CEO on CNBC that suggested Juxtapid can improve patient survival, which has not been studied in clinical trial. The firm expects the subpoena will result in more rigorous marketing practices controlled by compliance and a “manageable fine" and reiterates an Outperform rating on Aegerion.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
07:35 EDTAEGRCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 20, 2014
07:24 EDTAEGRAegerion price target lowered to $46 from $66 at Leerink
Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.
October 14, 2014
16:13 EDTAEGRPoint72 Asset Management reports 5.2% passive stake in Aegerion
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use